Climb Bio Q3 net loss widens 13% to $14.57 million

• Climb Bio’s third-quarter 2026 net loss widened 13% year over year to $14.57 million.
• Research and development expenses rose 22% year over year to $11.04 million.
• Cash, cash equivalents and marketable securities totaled $227.6 million at September 30, with runway expected into the second half of 2028.
• CLYM116 Phase 2 IgAN dosing began; initial data are expected in the first half of 2027.
• Initial budoprutug Phase 2 pMN data showed immunologic remission at 200 mg; additional cohort data are expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Climb Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050700PRIMZONEFULLFEED9870768) on November 05, 2026, and is solely responsible for the information contained therein.